{From a related web site}
In summary, our results indicate that ivermectin suppressed the AR and E2F signaling pathways and DNA damage repair capacity by targeting FOXA1 and Ku70/Ku80 to inhibit cell proliferation and promote cell apoptosis in prostate cancer. These findings provide insight into both the effects and mechanisms of ivermectin as an anticancer agent. This raises the possibility of broadening the clinical evaluation of ivermectin for the treatment of prostate cancer.
nature.com/articles/s41419-...
Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer. Pub med pubmed.ncbi.nlm.nih.gov/360...
[The pubmed version only has a limited portion of the whole.]